Interleukin-2 and the development of immunotherapy for the treatment of patients with cancer.

No abstract is available for this paper.

• Publication year

  2000

• Venue

  The cancer journal from Scientific American

• Publication date

  2000-02-01

• Fields of study

  Medicine

• Identifiers
  PMID 10685650
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen.

  1999cited by this paper
• A new era for cancer immunotherapy based on the genes that encode cancer antigens.

  1999cited by this paper
• Impact of cytokine administration on the generation of antitumor reactivity in patients with metastatic melanoma receiving a peptide vaccine.

  1999cited by this paper
• Biochemical Identification of a Mutated Human Melanoma Antigen Recognized by CD4+ T Cells

  1999cited by this paper
• Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response.

  1999cited by this paper
• Identification of a Novel Major Histocompatibility Complex Class II–restricted Tumor Antigen Resulting from a Chromosomal Rearrangement Recognized by CD4+ T Cells

  1999cited by this paper
• Trends in the safety of high dose bolus interleukin‐2 administration in patients with metastatic cancer

  1998cited by this paper
• Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

  1998cited by this paper
• Identification of a shared HLA-A*0201-restricted T-cell epitope from the melanoma antigen tyrosinase-related protein 2 (TRP2).

  1998cited by this paper
• A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening.

  1997cited by this paper
• Keynote address: perspectives on the use of interleukin-2 in cancer treatment.

  1997cited by this paper
• Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A.

  1997cited by this paper
• The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes.

  1997cited by this paper
• Cancer vaccines based on the identification of genes encoding cancer regression antigens.

  1997cited by this paper
• A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes

  1996cited by this paper
• Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen

  1996cited by this paper
• Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides.

  1996cited by this paper
• Vitiligo in patients with melanoma: normal tissue antigens can be targets for cancer immunotherapy.

  1996cited by this paper
• Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes

  1996cited by this paper
• Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues.

  1996cited by this paper
• Genes Coding for Tumor Antigens Recognized by Cytolytic T Lymphocytes

  1995cited by this paper
• Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes.

  1995cited by this paper
• Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes [published erratum appears in J Exp Med 1995 Mar 1;181(3):1261]

  1995cited by this paper
• Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.

  1994cited by this paper
• A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

  1994cited by this paper
• Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection.

  1994cited by this paper
• Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy.

  1994cited by this paper
• The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas

  1993cited by this paper
• Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2

  1985cited by this paper
• Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

  1984cited by this paper
• Structure and expression of a cloned cDNA for human interleukin-2

  1983cited by this paper
• Selective in vitro growth of T lymphocytes from normal human bone marrows.

  1976cited by this paper

• Adoptive transfer of natural killer cells in therapeutic treatment of COVID-19 patients

  2025cites this paper
• Combination LIGHT overexpression and checkpoint blockade disrupts the tumor immune environment impacting colorectal liver metastases

  2025cites this paper
• Natural killer cells in cancer immunotherapy

  2024cites this paper
• Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer.

  2023cites this paper
• Autologous engineered T cell receptor therapy in advanced cancer

  2023cites this paper
• Next Generation Natural Killer Cells for Cancer Immunotherapy

  2022cites this paper
• Evaluation of Anticancer Potential of Flavones from Rhamnus alaternus against B16F10 Melanoma Cells

  2021influential citation
• Cyclophosphamide, fluorouracil and low-dose interleukin-2 and salvage combination chemotherapy in advanced cutaneous squamous cell carcinoma

  2020cites this paper
• Cyclophosphamide with or without fluorouracil followed by subcutaneous or intravenous interleukin‐2 use in solid tumors: A feasibility off‐label experience

  2019cites this paper
• The VE-PTP Inhibitor AKB-9778 Improves Antitumor Activity and Diminishes the Toxicity of Interleukin 2 (IL-2) Administration

  2019cites this paper
• Safety of low-dose subcutaneous recombinant interleukin-2: systematic review and meta-analysis of randomized controlled trials

  2019cites this paper
• A comprehensive analysis of clinical trials including both immunotherapy and radiation therapy

  2018cites this paper
• A novel strategy to produce high level and high purity of bioactive IL15 fusion proteins from mammalian cells.

  2018cites this paper
• Targeted IL-15-based Protein Fusion Complexes as Cancer Immunotherapy Approaches

  2018cites this paper
• Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.

  2017cites this paper
• Natural killer cells in inflammatory heart disease.

  2017cites this paper
• Natural killer cell adoptive immunotherapy: Coming of age.

  2017cites this paper
• The Rise of Allogeneic Natural Killer Cells As a Platform for Cancer Immunotherapy: Recent Innovations and Future Developments

  2017cites this paper
• Immune targets and neoantigens for cancer immunotherapy and precision medicine

  2016cites this paper
• Glatiramer Acetate, Dimethyl Fumarate, and Monomethyl Fumarate Upregulate the Expression of CCR10 on the Surface of Natural Killer Cells and Enhance Their Chemotaxis and Cytotoxicity

  2016cites this paper
• Impact du G-CSF sur le phénotype et les fonctions des cellules NK dans le cadre d’une immunothérapie post-allogreffe de cellules souches hématopoïétiques

  2016cites this paper
• Whole Tumor Cell Vaccine Adjuvants: Comparing IL-12 to IL-2 and IL-15.

  2016cites this paper
• Contradicting interplay between insulin-like growth factor-1 and miR-486-5p in primary NK cells and hepatoma cell lines with a contemporary inhibitory impact on HCC tumor progression

  2016cites this paper
• the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy

  2015cites this paper
• The Shared and Contrasting Roles of IL2 and IL15 in the Life and Death of Normal and Neoplastic Lymphocytes: Implications for Cancer Therapy

  2015cites this paper
• Natural Killer Cell Adoptive Transfer Therapy: Exploiting the First Line of Defense Against Cancer.

  2015cites this paper
• Natural killer cells: In health and disease.

  2015cites this paper
• Understanding of molecular mechanisms in natural killer cell therapy

  2015cites this paper
• TheSharedandContrastingRolesof IL 2 and IL 15 in the Life and Death of Normal and Neoplastic Lymphocytes : Implications for Cancer Therapy

  2015cites this paper
• Utilizing Cytokines to Function-Enable Human NK Cells for the Immunotherapy of Cancer

  2014cites this paper
• Activation of NK Cell Responses and Immunotherapy of Cancer

  2014cites this paper
• Durable responses and reversible toxicity of high-dose interleukin-2 treatment of melanoma and renal cancer in a Community Hospital Biotherapy Program

  2014cites this paper
• delivery to the tumor blood vessel extracellular matrix Enhancement of the antitumor properties of interleukin-2 by its targeted

  2013cites this paper
• Tumor necrosis therapy antibody interleukin-2 fusion protein elicits prolonged and targeted antitumor effects in vivo

  2013cites this paper
• Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathology

  2013cites this paper
• Virus-Like Particles Harboring CCL19, IL-2 and HPV16 E7 Elicit Protective T Cell Responses in HLA-A2 Transgenic Mice

  2012cites this paper
• Enhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.

  2012cites this paper
• Natural killer cell lines in tumor immunotherapy

  2012cites this paper
• The role of natural killer cells in the immune response against CMV infection in immunosuppressed patients

  2011cites this paper
• Anti-IL-23 monoclonal antibody synergizes in combination with targeted therapies or IL-2 to suppress tumor growth and metastases.

  2011cites this paper
• Role of immune responses in the pathogenesis of low‐risk MDS and high‐risk MDS: implications for immunotherapy

  2011cites this paper
• Towards effective TCR gene therapy: preclinical requirements

  2010cites this paper
• Natural Killer Cells in the Treatment of Human Cancer

  2010cites this paper
• Tolerated Oral Agents Preclinical Anti-Tumor Activities as Phosphatase Inhibitor-1 and Analogs with Novel SHP-1 Inhibitors Tyrosine

  2010cites this paper
• Novel SHP-1 Inhibitors Tyrosine Phosphatase Inhibitor-1 and Analogs with Preclinical Anti-Tumor Activities as Tolerated Oral Agents

  2010cites this paper
• Delivering cytokines at tumor site: The immunocytokine-conjugated anti-EDB-fibronectin antibody case.

  2009cites this paper
• Modifying interleukin-2 concentrations during culture improves function of T cells for adoptive immunotherapy.

  2009cites this paper
• Uric Acid as a Growth Factor for Activated B Cells

  2009cites this paper
• Immunotherapy of Cancer

  2009cites this paper
• Sustained suppression of SHIV89.6P replication in macaques by vaccine-induced CD8+ memory T cells

  2008cites this paper
• NK cell-mediated targeting of human cancer and possibilities for new means of immunotherapy

  2008cites this paper
• Serum soluble interleukin 2 receptor α in human cancer of adults and children: a review

  2008cites this paper
• IL‐15 acts as a potent inducer of CD4+CD25hi cells expressing FOXP3

  2008cites this paper
• Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy

  2008cites this paper
• The regulation of NK cell function and development.

  2008cites this paper
• Development of natural killer cells from hematopoietic stem cells.

  2007cites this paper
• Cytokines in Human Health

  2007cites this paper
• A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients.

  2007cites this paper
• Prospects for the use of NK cells in immunotherapy of human cancer

  2007cites this paper
• Checkpoint blockade in cancer immunotherapy.

  2007cites this paper
• Enhancing Antitumor Immunity: Combining IL-12 With TGFβ1 Antagonism

  2007cites this paper
• Cytokine-Induced Vascular Leak Syndrome

  2007cites this paper
• Immunomodulation by inactivated Orf virus (ORFV) - therapeutic potential

  2007cites this paper
• Checkpoint Blockade and Combinatorial Immunotherapies

  2007cites this paper
• Experimental Models of Cytokines and Cancer Prevention

  2007cites this paper
• The Extended CD 28 : B 7 Immunoglobulin Superfamily

  2007cites this paper
• The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design

  2006cites this paper
• Microarray-based gene expression analysis for the investigation of immunologically relevant processes in tumors

  2006cites this paper
• The rationale for prophylactic cancer vaccines and need for a paradigm shift

  2006cites this paper
• The association between malignant melanoma and noncutaneous malignancies

  2006cites this paper
• Interleukin-2, interleukin-15, and their roles in human natural killer cells.

  2005cites this paper
• Role of trans-cellular IL-15 presentation in the activation of NK cell-mediated killing, which leads to enhanced tumor immunosurveillance.

  2005cites this paper
• Interleukin-2 family cytokines: potential for therapeutic immmunoregulation

  2005cites this paper
• Scale-up Purification of a Mutant of Recombinant Human Interleukin 2 by Reverse-phase High Performance Liquid Chromatography

  2005cites this paper
• Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma.

  2005cites this paper
• Sodium Stibogluconate Interacts with IL-2 in Anti-Renca Tumor Action via a T Cell-Dependent Mechanism in Connection with Induction of Tumor-Infiltrating Macrophages1

  2005influential citation
• Close encounters of different kinds: Dendritic cells and NK cells take centre stage

  2005cites this paper
• The role of natural killer cells in tumor control—effectors and regulators of adaptive immunity

  2005cites this paper
• Macrophages with Induction of Tumor-Infiltrating Cell-Dependent Mechanism in Connection Anti-Renca Tumor Action via a T Sodium Stibogluconate Interacts with IL-2 in

  2005influential citation
• Intratumoral Poly-N-Acetyl Glucosamine-Based Polymer Matrix Provokes a Prolonged Local Inflammatory Response That, When Combined with IL-2, Induces Regression of Malignant Mesothelioma in a Murine Model

  2005cites this paper
• Aging, immunity and cancer.

  2004cites this paper
• Potentiation of antitumor effect of NKT cell ligand, α-galactosylceramide by combination with IL-12 on lung metastasis of malignant melanoma cells1

  2004cites this paper
• Nitric Oxide Production in HIV-1 Infected Patients Receiving Intermittent Cycles of Interleukin-2 and Antiretrovirals

  2004cites this paper
• Cytokines in cancer immunity and immunotherapy

  2004cites this paper
• [Gene therapy of melanoma: review of published clinical trials].

  2003cites this paper
• Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.

  2003cites this paper
• T-Cell Depletion + Combination LEC / chTNT-3 Immunotherapy and CD 25 Complete Regression of Experimental Solid Tumors by Updated Version

  2003cites this paper
• CHAPTER 53 – Cytokines and cancer

  2003cites this paper
• Interleukin-2 for the Treatment of HIV Infection

  2003cites this paper
• Thérapie génique du mélanome : synthèse des études cliniques publiées

  2003cites this paper
• A Phase I Study of Nonmyeloablative Chemotherapy and Adoptive Transfer of Autologous Tumor Antigen-Specific T Lymphocytes in Patients With Metastatic Melanoma

  2002cites this paper
• Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells.

  2002cites this paper
• Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix.

  2002cites this paper
• Interleukin-2 and interleukin-15: immunotherapy for cancer.

  2002influential citation
• Immunotherapy for melanoma.

  2002cites this paper
• Immunomodulation with antibodies: clinical application in ovarian cancer and other malignancies

  2002cites this paper
• Isolation and characterization of modified species of a mutated (Cys125 -Ala) recombinant human interleukin-2.

  2002cites this paper
• Gene-expression profiling of the response of peripheral blood mononuclear cells and melanoma metastases to systemic IL-2 administration

  2002cites this paper
• Immunotherapy Blood T Cells : Implications for Cancer Expression in Human Peripheral γ IFN-Bryostatin-1 and IL-2 Synergize to Induce Aguero and

  2001cites this paper
• Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer

  2001cites this paper